SCHEMBL4605989

SCHEMBL4605989

CCC(=O)Nc1ccc(N)cc1C(=O)OC

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.51
HTT P42858 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 9/20 0.47
KDM4E B2RXH2 6/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 2/20 0.47
MAPT P10636 3/20 0.47
MAPK1 P28482 1/20 0.47
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
MAPK10 P53779 2/20 0.44
HSD17B10 Q99714 5/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4604248 0.84 CA12 (0.57) GAAHTTKMT2AALDH1A1KDM4E
SCHEMBL4605157 0.83 L3MBTL1 (0.55) HTTKMT2AALDH1A1KDM4ELMNA
SCHEMBL5627215 0.83 GAA (0.56) GAAKMT2AALDH1A1KDM4ELMNA
SCHEMBL17085329 0.83 GAA (0.56) GAAKMT2AALDH1A1KDM4EHPGD
SCHEMBL31196721 0.83 GAA (0.56) GAAKMT2AALDH1A1KDM4ELMNA
SCHEMBL22650326 0.82 HTT (0.50) GAAHTTKMT2AALDH1A1KDM4E
SCHEMBL4604562 0.82 ALDH1A1 (0.60) GAAHTTKMT2AALDH1A1KDM4E
SCHEMBL29441245 0.82 ALDH1A1 (0.60) GAAHTTKMT2AALDH1A1KDM4E
SCHEMBL1826967 0.79 HTT (0.48) GAAHTTKMT2AALDH1A1KDM4E
SCHEMBL4604780 0.79 KDM4E (0.60) GAAHTTKMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 GAA 864/4885HTT 3670/4885KMT2A 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.